{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Cerus Corp. technically bullish or bearish?
As of June 2, 2025, Cerus Corp. exhibits a mildly bearish trend, with mixed signals from indicators like the MACD showing mild bullishness, while Bollinger Bands and moving averages indicate bearishness on shorter time frames.
Who are in the management team of Cerus Corp.?
As of March 2022, the management team of Cerus Corp. includes Independent Chairman Mr. Daniel Swisher, President and CEO Mr. William Greenman, and several Independent Directors: Mr. Timothy Anderson, Mr. Eric Bjerkholt, Mr. Timothy Moore, Ms. Jami Nachtsheim, and Ms. Gail Schulze. They oversee the company's operations and strategic direction.
What does Cerus Corp. do?
Cerus Corporation is a biomedical company focused on developing the INTERCEPT Blood System for blood safety. As of March 2025, it has net sales of $43 million, a market cap of $250.42 million, and is currently operating at a loss.
How big is Cerus Corp.?
As of Jun 18, Cerus Corp. has a market capitalization of 250.42 million, with net sales of 185.15 million and a net profit of -18.99 million over the last four quarters. Shareholder's funds total 56.15 million, and total assets are valued at 200.92 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
